National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 6 of 6 Research Studies DisplayedBasu A, Sohn MW, Bartle B
Development and validation of the real-world progression in diabetes (RAPIDS) model.
This study investigated the value of using the real-world progression in diabetes (RAPIDS) model to increase medication inherence among Veterans Administration (VA) patients. Over 500,000 patients were tracked in 2003 with a 9-year followup. The model includes predictions as to outcomes and medication adherence and was found to be effective.
AHRQ-funded; HS018542.
Citation: Basu A, Sohn MW, Bartle B .
Development and validation of the real-world progression in diabetes (RAPIDS) model.
Med Decis Making 2019 Feb;39(2):137-51. doi: 10.1177/0272989x18817521..
Keywords: Comparative Effectiveness, Diabetes, Medication
Sharma A, Al-Khatib SM, Ezekowitz JA
Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes.
This study evaluates the effectiveness of a strategy that uses an implantable cardioverter-defibrillator (ICD) plus medical therapy versus medical therapy alone among patients with heart failure (HF) and diabetes. Researchers conducted a patient-level combined-analysis using a combined dataset that included four primary prevention ICD trials of patients with HF or severely reduced ejection fractions. The results indicate that primary prevention ICD in combination with medical therapy versus medical therapy alone was not significantly associated with a reduced risk of all-cause death. The authors conclude that further studies are needed to evaluate the effectiveness of ICDs among patients with diabetes.
AHRQ-funded; HS018505.
Citation: Sharma A, Al-Khatib SM, Ezekowitz JA .
Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes.
Eur J Heart Fail 2018 Jun;20(6):1031-38. doi: 10.1002/ejhf.1192..
Keywords: Cardiovascular Conditions, Comparative Effectiveness, Diabetes, Heart Disease and Health, Medical Devices, Prevention
Prentice JC, Conlin PR, Gellad WF
Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes.
This study used observational quasi-experimental methods using instrumental variables (IVs) to compare the effect of two hypoglycemic medications, sulfonylureas (SUs) and thiazolidinediones (TZDs), on long-term outcomes. It found that individuals who used an SU as a second-line agent experienced significantly more adverse long-term health outcomes than did individuals who started on a TZD.
AHRQ-funded; HS019708.
Citation: Prentice JC, Conlin PR, Gellad WF .
Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes.
Value Health 2014 Dec;17(8):854-62. doi: 10.1016/j.jval.2014.08.2674..
Keywords: Diabetes, Medication, Outcomes, Comparative Effectiveness
Zhang Y, McCoy RG, Mason JE
Second-line agents for glycemic control for type 2 diabetes: are newer agents better?
The researchers aimed to assess the benefits and harms of four commonly used antihyperglycemia treatment regimens considering clinical effectiveness, quality of life, and cost. According to the model used by the researchers, all regimens resulted in similar life years and quality-adjusted life years (QALYs) regardless of glycemic control goal, but the regimen with sulfonylurea incurred significantly lower cost per QALY.
AHRQ-funded; HS017628.
Citation: Zhang Y, McCoy RG, Mason JE .
Second-line agents for glycemic control for type 2 diabetes: are newer agents better?
Diabetes Care 2014;37(5):1338-45. doi: 10.2337/dc13-1901..
Keywords: Diabetes, Comparative Effectiveness, Quality of Life, Medication
Neugebauer R, Fireman B, Roy JA
Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes.
This study used comparative effectiveness research methods to compare the effect of four distinct glucose-control strategies on subsequent myocardial infarction and nephropathy in type 2 diabetes. It found that in a large group of adults with type 2 diabetes, more aggressive glucose-control strategies have mixed short-term effects on microvascular complications and do not reduce the myocardial infarction rate over 4 years of follow-up.
AHRQ-funded; 29020050033I.
Citation: Neugebauer R, Fireman B, Roy JA .
Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes.
Diabetes Care 2013 Nov;36(11):3510-6. doi: 10.2337/dc12-2675..
Keywords: Comparative Effectiveness, Diabetes, Outcomes, Patient-Centered Outcomes Research, Treatments
Raebel MA, Xu S, Goodrich GK
Initial antihyperglycemic drug therapy among 241 327 adults with newly identified diabetes from 2005 through 2010: a surveillance, prevention, and management of diabetes mellitus (SUPREME-DM) study.
This study sought to identify predictors of initiating any antihyperglycemic medication, and specifically sulfonylurea versus metformin in patients with newly diagnosed with diabetes. Most (59.7 percent) patients with newly diagnosed diabetes did not start any antihyperglycemic medication. Among those who did, metformin was generally the first antihyperglycemic initiated.
AHRQ-funded; HS019859
Citation: Raebel MA, Xu S, Goodrich GK .
Initial antihyperglycemic drug therapy among 241 327 adults with newly identified diabetes from 2005 through 2010: a surveillance, prevention, and management of diabetes mellitus (SUPREME-DM) study.
Ann Pharmacother. 2013 Oct;47(10):1280-91. doi: 10.1177/1060028013503624..
Keywords: Diabetes, Medication, Comparative Effectiveness